Europe should lead in coordinated procurement of quality-assured medicines for programmes in low-income and middle-income countries

Christophe Perrin, Sandrine Cloez, Catherine Dujardin, Raffaella Ravinetto

Research output: Contribution to journalA1: Web of Science-articlepeer-review

19 Downloads (Pure)

Abstract

Europe should lead in coordinated procurement of quality-assured medicines for programmThoughtful procurement policies in humanitarian and development medical programmes can mitigate the risk of purchasing poor-quality medicines, allowing to address fundamental moral obligation to equity, transparency and accountability. European donors are aware of the quality problems in the global pharmaceutical market, and some are already translating awareness into explicit procurement and quality assurance policies. However, a joint position and coordinated action is lacking.
European donors should share existing knowledge and tools, seek the input of recipient countries, and develop a joint position on how the donor community
can help to ensure access to affordable and quality-assured health products—also during public health emergencies such as the COVID-19 pandemic.
Applying stringent and harmonised quality assurance requirements, European donors and their implementing organisations can help shaping the global pharmaceutical market towards affordable, quality assured products.es in low-income and middle-income countries
Original languageEnglish
Article numbere003283
JournalBMJ Global Health
Volume5
Issue number7
Number of pages5
ISSN2059-7908
DOIs
Publication statusPublished - 2020

Keywords

  • Developing Countries
  • Europe
  • Health Services Accessibility
  • Humans
  • Income
  • Poverty

Fingerprint

Dive into the research topics of 'Europe should lead in coordinated procurement of quality-assured medicines for programmes in low-income and middle-income countries'. Together they form a unique fingerprint.

Cite this